Christoph U. Correll, MD (Activity Chair)
Professor of Psychiatry
Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New York, New York

 Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC
Psychiatric Associates of Central Texas
Affiliate faculty, University of Texas at Austin School of Nursing
Austin, Texas

Leigh Anne Nelson, PharmD, BCPP
Associate Professor
University of Missouri Kansas City School of Pharmacy
Kansas City, Missouri

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Christoph U. Correll, MD–has disclosed that he is a consultant for Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He also receives grant/research from Janssen and Takeda. 
Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine.  

Faculty
Christoph U. Correll, MD–has disclosed that he is a consultant for Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He also receives grant/research from Janssen and Takeda. 
Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Leigh Anne Nelson, PharmD, BCPP–has disclosed that she receives grant/research support from Alkermes, Auspex, Boehringer-Ingelheim, and Neurocrine. 

Content Reviewers
Andrew Cutler, MD-has disclosed that he is a consultant for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion; he receives grant/research support from Alkermes IntraCellular Therapies Janssen, Lundbeck, Otsuka, and Sunovion. He also is a member of the speakers’ bureau for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion.
Deanna Kelly, PharmD, BCPP–has disclosed that she is consultant for Alkermes.
Amanda Simonton, ARNP–has disclosed that she is on a Medscape Education Steering Committee that is supported by grant money from Alkermes.